Pharmaceuticals News and Research

RSS

BWH Karp Laboratory acquires BioFlux 1000 system for stem cell homing research

Fluxion Biosciences announced today that the Karp Laboratory at the Brigham and Women's Hospital (BWH) has purchased the BioFlux 1000 system, which will be applied in their stem cell homing research.

From Fluxion Biosciences 12 May 2011

FDA accepts EffRx NDA for EX101 to treat osteoporosis

EffRx Pharmaceuticals SA, an Epalinges/Lausanne, Switzerland based drug delivery company announces that the New Drug Application for the company's lead development program EX101 has been accepted for filing by the US Food and Drug Administration.

12 May 2011

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Halozyme Therapeutics, Inc. and ViroPharma Incorporated, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous formulation of Cinryze .

12 May 2011

Viewpoints: Tea Party on entitlement reform; Boehner's 'trillions' demand; California's silver tsunami

In a speech on Monday, the speaker of the House said that Republicans would insist on trillions of dollars in spending cuts in exchange for votes to raise the debt limit. He did not mention a time frame. He also did not offer specifics on how he planned to make those cuts. After the beating Republicans took for their plan to slash Medicare, he clearly decided generalities were politically safer. There is no way to solve the country's fiscal ills without an accurate diagnosis and rigorous prescriptions for a cure. Mr. Boehner's speech was devoid of both.

12 May 2011

American Medical Alert first quarter net income increases 18% to $1,046,378

American Medical Alert Corp. a provider of healthcare communication services and advanced telehealth monitoring technologies, today announced operating results for the quarter ended March 31, 2011, the

11 May 2011

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.

11 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

China Pharma first quarter revenue increases 20% to $18.1 million

China Pharma Holdings, Inc., a fully-integrated specialty pharmaceuticals company in China, today announced financial results for the quarter ended March 31, 2011.

11 May 2011

Baylor has now patented new polarimeter that could prove useful in pharmaceuticals

Two Baylor University chemistry professors have invented a new polarimeter, a basic scientific instrument used to measure and interpret the polarization of transverse waves, such as light waves, that could prove useful in determining the purity of pharmaceuticals. Baylor has now patented the device.

11 May 2011

Symphogen to present second-generation Sympress platform at ESACT conference

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.

11 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

TSA, Psyadon Pharmaceuticals partner for ecopipam clinical trial in Tourette Syndrome

The national Tourette Syndrome Association and Psyadon Pharmaceuticals Inc. are pleased to announce their collaboration on a clinical trial to determine the potential efficacy of a novel drug, ecopipam, for managing the symptoms of the neurological disorder Tourette Syndrome.

11 May 2011

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and reiterated 2011 financial guidance.

11 May 2011

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

The Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals, Inc. announced today that they have entered into a research collaboration agreement to provide financial support for a series of clinical studies to investigate the feasibility of mixing pramlintide, an analog of the human hormone amylin, with insulin to treat type 1 diabetes.

11 May 2011

Impax Pharmaceuticals initiates IPX159 Phase I study in Restless Legs Syndrome

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., announced the successful filing of an Investigational New Drug Application for IPX159 in Restless Legs Syndrome and initiated a Phase I study.

11 May 2011

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that GATTEX, a novel, recombinant analog of human glucagon-like peptide 2, was found to effectively and safely reduce parenteral support volume in adult short bowel syndrome-intestinal failure patients.

11 May 2011

ICON partners with BCRI for clinical research

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced a strategic alliance with Boston Clinical Research Institute, an Academic Research Organisation based in Boston, Massachusetts.

11 May 2011

Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 2011 Digestive Disease Week conference highlighting additional analyses of data from Phase 3 trials of DIFICID, an investigational product for the treatment of Clostridium difficile infection.

11 May 2011

U.S. biopharmaceutical companies to benefit from Almac's European Product Launch workshop

Almac is hosting its inaugural European Product Launch workshop in Boston, MA on 17th May 2011. Targeted specifically at the biopharmaceutical sector, the workshop provides consultative advice and services to US companies to successfully launch drug products onto the European market.

11 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

Pharmaceuticals News and Research

BWH Karp Laboratory acquires BioFlux 1000 system for stem cell homing research

FDA accepts EffRx NDA for EX101 to treat osteoporosis

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Viewpoints: Tea Party on entitlement reform; Boehner's 'trillions' demand; California's silver tsunami

American Medical Alert first quarter net income increases 18% to $1,046,378

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

China Pharma first quarter revenue increases 20% to $18.1 million

Baylor has now patented new polarimeter that could prove useful in pharmaceuticals

Symphogen to present second-generation Sympress platform at ESACT conference

Naurex announces completion of $18 million Series A financing

TSA, Psyadon Pharmaceuticals partner for ecopipam clinical trial in Tourette Syndrome

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Amylin, JDRF collaborate to investigate combination therapy for type 1 diabetes treatment

Impax Pharmaceuticals initiates IPX159 Phase I study in Restless Legs Syndrome

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

ICON partners with BCRI for clinical research

Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference

U.S. biopharmaceutical companies to benefit from Almac's European Product Launch workshop

Inovio first quarter total revenue increases to $3.1 million for 2011

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence